T. D. De Pas

发表

Thymic epithelial tumors: From biology to treatment.

G. Giaccone, F. Conforti, L. Pala, 2020, Cancer treatment reviews.

Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents

D. Radice, F. D. De Braud, G. Curigliano, 2010, Oncology.

Review Article: Pulmonary Sarcomatoid Carcinomas: A Practical Overview

G. Pelosi, D. Galetta, G. Veronesi, 2010, International journal of surgical pathology.

Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion

G. Giaccone, R. Gelber, C. Swanton, 2021, Clinical Cancer Research.

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

L. Spaggiari, F. D. De Braud, A. Delmonte, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.

L. Spaggiari, F. D. De Braud, G. Curigliano, 2006, Lung cancer.

Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.

F. Conforti, L. Pala, C. Catania, 2017, Future oncology.

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

T. Mok, R. Salgia, E. Felip, 2017, Cancer treatment reviews.

Complex renal cysts associated with crizotinib treatment

A. Shaw, Weiwei Tan, K. Wilner, 2015, Cancer medicine.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Michael Thomas, Takashi Seto, Kazuhiko Nakagawa, 2013, The New England journal of medicine.

EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non–Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials

C. Specchia, F. de Marinis, P. Queirolo, 2020, JNCI cancer spectrum.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

F. de Marinis, M. Barberis, C. Fumagalli, 2015, OncoTargets and therapy.

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

H. Joensuu, P. Casali, C. Spreafico, 2011, British Journal of Cancer.

Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.

H. Joensuu, P. Casali, C. Spreafico, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial

Michael Thomas, Armando Santoro, Martin Schuler, 2016, The Lancet. Oncology.

Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials

R. Gelber, M. Piccart, P. Arnone, 2023, Breast.

Participation in Clinical Trials as Viewed by the Patient: Understanding Cultural and Emotional Aspects Which Influence Choice

D. Radice, A. Goldhirsch, F. D. De Braud, 2008, Oncology.

Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis

F. Grosso, P. Casali, S. Ferrari, 2022, Frontiers in Oncology.

Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy

A. Santoro, S. Bozzarelli, L. Giordano, 2021, Cancer.

The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis.

L. Mariani, O. Mir, A. D. Dei Tos, 2020, The oncologist.

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study

C. Gridelli, S. Thongprasert, E. Felip, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung.

A. Delmonte, M. Santarpia, M. Duca, 2013, Lung cancer.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

A. Marchetti, F. Buttitta, A. Chella, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

S. Barni, V. Torri, S. Novello, 2014, The Lancet. Oncology.

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment

A. Marchetti, F. Buttitta, A. Chella, 2014, PloS one.

Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors

F. de Marinis, M. Barberis, F. Conforti, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.

L. Spaggiari, G. Altavilla, R. Rosell, 2013, Future oncology.

Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.

R. Labianca, L. Spaggiari, M. Giovannini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine-induced systemic capillary leak syndrome.

L. Spaggiari, G. Curigliano, F. de Braud, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of mandibular dose distribution in radiotherapy for oropharyngeal cancer: dosimetric and clinical results in 18 patients.

R. Orecchia, A. d’Onofrio, C. Bocci, 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Roberto Scalamogna, Vanesa Gregorc, F. D. De Braud, 2011, Clinical Cancer Research.

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.

G. Ceresoli, F. D. De Braud, P. Bruzzi, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen.

A. Goldhirsch, A. Gallino, G. Martinelli, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.

T. De Pas, C. Sessa, R. Johnson, 2002, European journal of cancer.

Stem cell transplantation effectively occludes bronchopleural fistula in an animal model.

F. Acocella, F. Petrella, L. Spaggiari, 2014, The Annals of thoracic surgery.

Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil.

M. Aapro, F. Debraud, E. Munzone, 1998, American journal of clinical oncology.

Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era.

G. Veronesi, L. Spaggiari, F. D. De Braud, 2007, The Annals of thoracic surgery.

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.

R. Gelber, A. Goldhirsch, G. Viale, 2018, The Lancet. Oncology.

Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

A. Testori, F. Verrecchia, G. Mazzarol, 2012, Clinical & Experimental Metastasis.

The sacral chordoma margin.

P. Georg, P. Navarria, D. Campanacci, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).

V. Torri, M. Scorsetti, G. Apolone, 2018, Cancer treatment reviews.

Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group.

G. Curigliano, G. Lo Russo, P. Zucali, 2022, European journal of cancer.

Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials

G. Giaccone, F. Conforti, L. Pala, 2022, Expert Opinion on Investigational Drugs.

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

A. Chella, A. Santoro, M. Tiseo, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study

Robin L. Jones, J. Blay, O. Mir, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

A 10-Year Single-Center Experience on 708 Lung Metastasectomies: The Evidence of the “International Registry of Lung Metastases”

F. Petrella, A. Borri, M. Casiraghi, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Breast phyllodes tumor: a review of literature and a single center retrospective series analysis.

A. Luini, A. Goldhirsch, G. Viale, 2013, Critical reviews in oncology/hematology.

1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC).

N. Altorki, P. Therasse, T. Mitsudomi, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

J. Engelman, Michael Thomas, A. Shaw, 2014, The New England journal of medicine.

Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study.

Robin L. Jones, J. Blay, M. Toulmonde, 2022, European journal of cancer.

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

F. de Marinis, L. Preda, M. Barberis, 2014, OncoTargets and therapy.

Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials

G. Giaccone, R. Gelber, C. Specchia, 2022, JAMA Network Open.

Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare.

G. Pelosi, G. Veronesi, L. Spaggiari, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast metastases from cutaneous malignant melanoma.

A. Luini, F. Bassi, B. Ballardini, 2004, Breast.

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

T. De Pas, J. Pujol, M. Debois, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Moon Soo Kim, N. Altorki, P. Therasse, 2016, The Lancet. Oncology.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer

G. Pelosi, G. Veronesi, L. Spaggiari, 2010, Acta oncologica.

Recurrence and prognostic factors in patients with aggressive fibromatosis. The role of radical surgery and its limitations

A. Testori, G. Viale, T. De Pas, 2012, World Journal of Surgical Oncology.

An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

Umberto Ricardi, Suresh Senan, Giulio Melloni, 2014, Clinical lung cancer.

Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.

P. Solli, G. Veronesi, L. Spaggiari, 2012, Critical reviews in oncology/hematology.

Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung Cancer

F. D. De Braud, G. Curigliano, R. Danesi, 2003, Pharmacological Reviews.

A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors.

F. D. De Braud, S. Cascinu, F. Braud, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?

T. De Pas, S. Franzi, R. Mantegazza, 2017, Oncotarget.

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?

E. Giovannetti, G. Peters, F. Toffalorio, 2012, Pharmacogenomics.

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.

G. Curigliano, P. Queirolo, P. Ferrucci, 2022, European journal of cancer.

Successful treatment with avapritinib in patient with mucosal metastatic melanoma

P. Ferrucci, F. Conforti, L. Pala, 2020, Therapeutic advances in medical oncology.

Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis

P. Queirolo, G. Mazzarol, C. Casali, 2022, Molecular Diagnosis & Therapy.

Prognostic role of lymph node involvement in lung metastasectomy.

F. Petrella, G. Pelosi, D. Galetta, 2007, The Journal of thoracic and cardiovascular surgery.

Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases.

A. Luini, F. D. De Braud, A. Testori, 2008, Critical reviews in oncology/hematology.

Sarcoma of the breast: outcome and reconstructive options.

A. Luini, P. Veronesi, E. Marrazzo, 2012, Clinical breast cancer.

Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma.

F. Orsi, F. D. De Braud, G. Curigliano, 2003, Anticancer research.

Immunotherapy of advanced renal cell carcinoma

F. D. De Braud, M. Maffezzini, T. de Pas, 1996 .

Sex and cancer immunotherapy: Current understanding and challenges.

G. Giaccone, R. Gelber, S. Minucci, 2022, Cancer cell.

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

R. Gelber, C. Specchia, G. Viale, 2021, BMJ.

Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations.

R. Gelber, M. Buyse, M. Piccart, 2022, JAMA oncology.

Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.

A. Delmonte, M. Santarpia, M. Barberis, 2014, Critical reviews in oncology/hematology.

Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis.

F. Orsi, A. Goldhirsch, F. D. De Braud, 2006, Supportive cancer therapy.

Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer.

U. Pastorino, L. Spaggiari, A. Goldhirsch, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Different Response to Immunotherapy According to Melanoma Histologic Subtype

P. Queirolo, G. Mazzarol, V. Bagnardi, 2021, Journal of immunotherapy.

Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden.

A. Goldhirsch, M. Aapro, S. Monti, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary and recurrent retroperitoneal soft tissue sarcoma: Prognostic factors affecting survival

A. Testori, A. Zbar, E. Bertani, 2006, Journal of surgical oncology.

Phase II Trial of Vinorelbine, Cisplatin and Continuous Infusion of 5-Fluorouracil Followed by Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer

F. D. De Braud, R. Orecchia, G. Catalano, 2002, Oncology.

Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.

G. Pelosi, F. D. De Braud, G. Curigliano, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

M. Socinski, R. Govindan, A. Shaw, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3).

R. Kaiser, A. Dingemans, A. Hackshaw, 2018, Lung cancer.

Molecular features and clinical outcome of lung malignancies in very young people.

L. Spaggiari, F. de Marinis, T. De Pas, 2015, Future oncology.

Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial.

G. Giaccone, L. Spaggiari, J. Vansteenkiste, 2019, European Journal of Cancer.

Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib

G. Pelosi, F. D. De Braud, G. Curigliano, 2007, The Prostate.

Features and Prognostic Factors of Large Node-Negative Non–Small-Cell Lung Cancers Shifted to Stage II

D. Radice, P. Solli, G. Veronesi, 2012, Journal of Thoracic Oncology.

Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

A. Bottomley, A. Shaw, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence

R. Gelber, A. Goldhirsch, G. Viale, 2019, Breast Cancer Research.

Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations☆

C. Sotiriou, R. Gelber, M. Piccart, 2021, Breast.

Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials

G. Giaccone, P. Queirolo, V. Bagnardi, 2021, ESMO open.

Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.

Yi-Song Wang, G. Giaccone, Justine N. McCutcheon, 2017, Cancer research.

Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.

R. Gelber, F. de Marinis, A. Goldhirsch, 2019, Journal of the National Cancer Institute.

Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer.

G. Pelosi, G. Veronesi, L. Spaggiari, 2005, The Annals of thoracic surgery.

Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization

M. Alloisio, E. Salvi, R. Mantegazza, 2023, Biomedicines.

Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity

F. D. De Braud, G. Curigliano, O. de Cobelli, 2007, Anti-cancer drugs.

SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis

G. Curigliano, P. Queirolo, Z. Ballatore, 2022, European Journal of Cancer.

Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.

G. Pelosi, F. D. De Braud, T. De Pas, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Imaging of lung hamartomas by multidetector computed tomography and positron emission tomography.

G. Pelosi, G. Veronesi, L. Spaggiari, 2008, The Annals of thoracic surgery.

EGFR Inhibition in a Pretreated Sacral Chordoma: A Role for Erlotinib? Case Report and a Brief Review of Literature

D. Trapani, F. Conforti, T. D. De Pas, 2017, Translational medicine @ UniSa.

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review

F. Conforti, L. Pala, D. Laszlo, 2023, Current oncology.

Optimizing Clinical Care in Patients with Advanced Soft Tissue Sarcoma: A Phase II Study of a New Schedule of High-Dose Continuous Infusion Ifosfamide and Doxorubicin Combination

D. Radice, C. Boni, T. De Pas, 2011, Chemotherapy.

Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action.

F. Conforti, L. Pala, T. de Pas, 2022, Seminars in oncology.

Boosting anticancer immunotherapy through androgen receptor blockade.

F. Conforti, L. Pala, T. de Pas, 2022, Cancer cell.

Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment.

A. Goldhirsch, G. Viale, R. Gelber, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment.

A. Goldhirsch, G. Viale, R. Gelber, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of systemic chemotherapy in a patient with mitochondrial myopathy and non-small-cell lung cancer.

N. Bresolin, G. Comi, A. Delmonte, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ifosfamide in the elderly: clinical considerations for a better drug management.

F. D. De Braud, G. Curigliano, A. Comandone, 2000, Critical reviews in oncology/hematology.

High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?

A. Goldhirsch, M. Aapro, N. Fazio, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Endometrial malignant melanoma rediagnosed as clear-cell "sugar" tumour.

R. Orecchia, H. Marsiglia, Carlos Miró, 2002, The Lancet. Oncology.

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

F. D. De Braud, G. Curigliano, A. Gambino, 2008, Ecancermedicalscience.

Adjuvant Treatment of High-risk Adult Soft Tissue Sarcomas: A Survey by the Italian Sarcoma Group

E. Barbieri, M. Berretta, G. Apice, 2006, Tumori.

Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine.

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2001, Lung cancer.

Gemcitabine, ifosfamide, cisplatin (GIP) for the treatment of advanced non‐small cell lung cancer: A phase II study of the Italian oncology group for clinical research (goirc)

C. Boni, G. Bisagni, R. Vignoli, 2000, International journal of cancer.

Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song.

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

P. Queirolo, C. Jemos, E. Omodeo Salè, 2020, Seminars in Oncology.

The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study

D. Radice, A. Goldhirsch, A. Delmonte, 2014, Psycho-oncology.

5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer

E. Giovannetti, N. Funel, G. Peters, 2018, Oncotarget.

A phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate.

F. D. De Braud, H. Joensuu, P. Casali, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative chemotherapy is essential for conservative surgery of Askin tumors.

U. Pastorino, P. Solli, G. Veronesi, 2003, The Journal of thoracic and cardiovascular surgery.

Cisplatin, Etoposide and Continuous Infusion Bleomycin in Patients with Testicular Germ Cell Tumors: Efficacy and Toxicity Data from a Retrospective Study

A. Goldhirsch, G. Curigliano, G. Martinelli, 2009, Journal of chemotherapy.

Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer.

S. Zambito, G. Curigliano, T. De Pas, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group

G. Pelosi, F. D. De Braud, T. De Pas, 2003, British Journal of Cancer.

Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas?

R. Labianca, F. D. De Braud, P. Casali, 2003, Oncology.

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer ( NSCLC ) : updated results from the phase 1 , multicentre , open-label ASCEND-1 trial

Michael Thomas, A. Shaw, Gregory Riely, 2016 .

Optimizing Pemetrexed-Gemcitabine Combination in Patients with Advanced Non-small Cell Lung Cancer: A Pharmacogenetic Approach

Francesca Russo, Giuseppe Pelosi, Davide Radice, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration.

L. Spaggiari, F. D. De Braud, C. Noberasco, 2009, Annals of Oncology.

Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.

G. Curigliano, R. Danesi, S. Fogli, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction chemoradiotherapy for superior sulcus non-small-cell lung cancer: an answer for few.

F. Petrella, P. Solli, G. Veronesi, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

A. Goldhirsch, F. D. De Braud, G. Curigliano, 2008, European journal of cancer.

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer

G. Pelosi, G. Veronesi, L. Spaggiari, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study

Ying Cheng, Keunchil Park, R. Ramlau, 2019, AntiCancer Research.

The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers

G. Curigliano, A. Gronchi, B. Vincenzi, 2023, Cancer medicine.

PROSE: Randomized proteomic stratified phase III study of second line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (NSCLC).

S. Barni, S. Novello, F. de Marinis, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.

D. Gomez, G. Melloni, S. Senan, 2014, Clinical lung cancer.

Three-times daily radiotherapy after chemotherapy in stage III non-small cell lung cancer. Single-institution prospective study.

G. Veronesi, L. Spaggiari, F. D. De Braud, 2008, Anticancer research.

Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease.

U. Pastorino, L. Spaggiari, F. D. De Braud, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.

J. Engelman, A. Shaw, E. Felip, 2013 .

CDX-2 should be included in the work-up of patients with lung metastases from unknown primary.

L. Spaggiari, A. Goldhirsch, F. D. De Braud, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome.

A. Goldhirsch, L. Nezi, P. Ferrucci, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).

S. Barni, V. Torri, S. Novello, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pulsed Dose-Rate Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas of the Extremities and Skeletal Muscles of the Trunk

L. Mariani, G. Pelosi, A. Testori, 2005, Annals of Surgical Oncology.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

M. Zucchetti, F. D. De Braud, A. Delmonte, 2014, The Oncologist.